Tiziana Life Sciences Ltd(TLSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:07 PM ET (Korea 10/31 05:07)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.2 | Insider Own | 49.84% | Shs Outstand | 128.0M | Perf Week | -15.8% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | -5.87% | Insider Trans | 1.57% | Shs Float | 64.4M | Perf Month | -29.82% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 2.02% | Short Float | 4.34% | Perf Quarter | -17.47% |
| Income | -0.03B | P/S | - | EPS this Y | -5.19% | Inst Trans | -14.81% | Short Ratio | 3.66 | Perf Half Y | -40.3% |
| Sales | 0.00B | P/B | - | EPS next 5Y | -4.82% | ROA | -178.26% | Short Interest | 2.79M | Perf YTD | -46.31% |
| Book/sh | -0.02 | P/C | 32.28 | EPS past 3/5Y | -0.89% -0.19% | ROE | -780.6% | 52W High | -59.18% ($1.96) | Perf Year | -56.52% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5.06% ($0.76) | Perf 3Y | 24.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -78.92% | Gross Margin | - | Volatility(W/M) | 7.69% 7.29% | Perf 5Y | -48.72% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.69 | EPS Q/Q | -101.04% | Profit Margin | - | RSI (14) | 33.27 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.69 | Sales Q/Q | - | SMA20 | -21.26% ($1.02) | Beta | 0.44 | Target Price | $7.97 |
| Payout | - | Debt/Eq | - | Earnings | 2026/09/18 | SMA50 | -20.4% ($1.01) | Rel Volume | 1.69 | Prev Close | $0.9 |
| Employees | 10 | LT Debt/Eq | - | EPS/Sales Surpr. | 1.5% - | SMA200 | -34.1% ($1.21) | Avg Volume(3M) | 0.76M | Price | $0.8 |
| IPO | 2018/11/20 | Option/Short | Yes/Yes | Trades | 1541 | Volume | 1,292,068 | Change | -11.57% |
🧬 A clinical-stage immunotherapy developer focused on an intranasal antibody therapy platform, advancing drug candidates for central nervous system diseases such as multiple sclerosis and Alzheimer's. With no commercialized products yet, the company generates no revenue, and as an early-stage biotech, its stock price is heavily influenced by clinical trial results and fundraising activities.
Over the past 1 year, on the lower side
59% below its 1-year high.
Traded more than usual. That is 169% of its average volume.
TLSA has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -5.2% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -48.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.0%.
Tap to view numbers
It ranks #349 of 595 in the industry
Based on market cap of $103M.
UNCY#348 Unicycive Therapeutics Inc $104M PER - TLSA#349 Tiziana Life Sciences Ltd $103M PER - 
ENGN#350 enGene Therapeutics Inc $103M PER - 
IMUX#351 Immunic Inc $102M PER - 
BDTX#352 Black Diamond Therapeutics Inc $102M PER - 
FAQ
What kind of company is TLSA?
TLSA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TLSA?
The market cap of TLSA is approximately $103M, ranking 4,443 within its sector.
What is the 52-week high and low for TLSA?
TLSA has recorded a 52-week high of $1.96 and a low of $0.76.
